Frequently asked questions (FAQ)

NBS is a system that helps to determine whether your baby is at has a higher risk for having a disorder for which early treatment or management can prevent intellectual disability, physical disability, or even early death. The screening involves a blood test called heel-prick test. NBS is usually performed when your baby is 24-48 hours old.
Most babies with the disorders included in newborn screening look and act normally and seem perfectly healthy. Newborn screening helps alert health care providers about a possible problem with your baby before it causes illness. Most babies who are diagnosed early and treated promptly do well. The earlier the disorder is detected, the higher the chance of having a good prognosis.
Parents who have no family history of these conditions and/or who have already had healthy children can still have children with these conditions. In fact, most children with these conditions are born into families with no history of the condition.
The test is performed by pricking your baby’s heel and putting a few drops of blood on a special filter paper. The paper is allowed to dry and then sent to the newborn screening laboratory where several different tests are performed.
The test is performed by pricking your baby’s heel and putting a few drops of blood on a special filter paper. The paper is allowed to dry and then sent to the newborn screening laboratory where several different tests will be performed.
During New born screening process, blood is collected from the baby’s heel onto a card (see a picture of a blood spot card below) and used for screening tests. These cards also record some personal information including the baby’s name, mother’s name, baby’s date of birth, address, and contact details of the referring doctor. 2
The blood test is generally performed when a baby is 24 to 48 hours old. This timing is important because certain conditions may go undetected or you may get false positive result, if the blood sample is drawn before 24 hours of age. If the blood is drawn after 48 hours of age, there could be a life-threatening delay in providing care to an infant that has the condition. This precaution ensures that parents and health professionals have the most accurate results. Ideally, the newborn hearing screen should be performed before the baby leaves the hospital.
It is preferable to wait for a baby to be on milk feeds prior to newborn blood spot screening. The results of metabolic disorders may come false negative.
Heal prick procedure is not likely to cause significant discomfort to your baby. The following suggestions may help make the screening experience more comfortable for you and your baby:

  1. Nurse/feed the baby before and/or after the procedure.
  2. Hold the baby during the procedure.
  3. Make sure the baby is warm and comfortable during the procedure.

Studies show that when mothers or health professionals comfort babies during the heel stick, the babies are less likely to cry.

The newborn screening program at Innovative Life Discoveries has been developed as per international norms. The NBS panels cover all disorders recommended in the ACMG core and secondary screening panels and a few additional ones.
Normal screening results will be communicated to the parents and/or health care provider by preferred mode of communication, as per the turnaround time (TAT) for the test. Abnormal screening results will be intimated by phone and/or email to the parents and/or healthcare provider as soon as the laboratory results are available. An abnormal newborn screen result does not necessarily mean your baby is ill. It may occur because the blood sample was collected too soon after birth, not enough blood was obtained, or your infant did not have enough breast or bottle feedings prior to the testing. However, sometimes an out-of-range result indicates a serious, but treatable, health problem. It is important for parents to follow up with the baby’s primary healthcare provider immediately to learn the cause of the out-of-range result.
You will be contacted if your baby needs additional testing. This does not mean that your baby is sick. Your baby may need some more tests. Your baby’s health professional will let you know what tests are needed and how to get them. It is very important that you get these tests done to make sure that your baby is healthy. If your baby is sick, treatment may be needed right away.
There are two main reasons why a repeat screening test may be needed:

  1. There was a problem with the way the first blood sample was collected; OR
  2. The test result was abnormal.

To repeat the newborn screening test, a new blood sample is needed from your baby. The newborn screening test is most accurate if your baby’s blood is taken after the first 24 hours of life. If your baby’s blood was collected before 24 hours of age, your doctor may ask you to repeat the test when your baby is 1 to 2 weeks old. Repeat sample after a borderline result is processed free of charge.

Your baby’s health professional will contact you if your baby needs to be retested. They will tell you why the baby needs to be retested and what to do next. A retest does not mean that your baby is sick, but more testing needs to be done to be sure that your baby is healthy. If your baby needs to be retested, get it done right away.
Each disorder is different. Some are treated with a special diet and others with medicine. If treated early, many babies grow up to lead a normal, healthy life. In a few cases, the disorders may not be completely treatable. Early diagnosis and treatment will allow your baby the best chance of normal growth and development.
No. Just as eye color or height cannot be changed, disorders of body chemistry cannot be cured. These disorders are caused by “mistakes” in the genes that cannot be corrected. However, the serious effects of many of these disorders can be prevented or lessened if a particular diet or medication is started early.
New Born screening at birth is mandatory in most developed countries and the technology that is used at Innovative Life Discoverieshas been validated on millions of infants.
Babies who are premature, unwell, or have had blood transfusions should all have the newborn blood sample taken as usual between 5 and 8 days of age AND this information recorded on the blood spot card. It is very important that the test is taken at the usual age so there is no risk of a baby going untested. If a baby is born at less than 32 weeks an additional test is needed for congenital hypothyroidism at 28 days of age or discharge home from hospital, whichever is sooner.
Screening of older children may be beneficial; however, this should be discussed with your baby’s docotr.
Newborn screening is just the first step in determining whether a baby has a condition. If a screening result is outside the typical range, diagnostic testing must be done to confirm the condition.
Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth. Using gene expression testing to help design a tailored treatment plan is called personalized medicine. These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer. Your physician will assess many factors prior to determining your treatment plan, including the size of the tumor, lymph node involvement, and the hormone receptor status of your cancer. These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.
Ask your doctor to run MammaPrint ® and BluePrint ® testing together on your breast cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage. No new biopsy or surgical tissue sample is typically required. iLife Discoveries Oncology Specialists can assist your doctor in getting this done.
MammaPrint is a unique test which analyses how aggressive your breast tumor is. The result of your MammaPrint test will assist you and your physician in determining what would be the best treatment for you following your operation.
MammaPrint is most suitable if breast cancer is still at an early stage. Ask your physician whether MammaPrint would be useful in your condition.
Your physician can request the test to be performed. Please discuss this with your physician.
No, MammaPrint is not a treatment or cure. It is a tool used to make a more accurate diagnosis. It can be used to determine how aggressive your type of breast cancer is. MammaPrint will however help you decide what would be the most appropriate treatment for you.
You wish to receive the best possible breast cancer treatment. MammaPrint will enable you to choose a treatment which is specifically tailored to you. Over 75% of breast cancer patients in the Netherlands receive chemotherapy treatment, even though it is a well known fact that this heavy treatment is unnecessary for many of them. As many as half of breast cancer patients receive chemotherapy which they do not benefit from in any way, but nevertheless experience the side effects. If these women had been able to make a decision based on precise information obtained from MammaPrint, they could have
MammaPrint is suitable for all types of breast cancer at an early stage, i.e. for ER+ and ER lymph node negative and positive (1-3) tumors in stages 1 and 2.
The physician takes a small piece of tissue from the tumors which has been removed, and sends the FFPE Block of this tissue to iLife Discoveries Laboratory.
This implies that statistically there is a 30% chance of metastasis within ten years. But supplementary therapy could reduce this risk. The MammaPrint can be used to determine in greater detail what your specific risk of metastasis is. You will then know whether chemotherapy would be appropriate for your tumor.
The chances of survival are excellent. Over the past twenty years prospects have radically improved. Especially if you have been diagnosed at an early stage, your chance of being cured will be very high. The fall in death rate is greatest among women between 50 and 75 years of age, i.e. the group which is invited for national breast cancer screening.
No, a different kind of test would need to be carried out. This test focuses on the hereditary forms of breast cancer, which can be identified in the BCRA-1 or BCRA-2 gene.
It takes fifteen working days to get the MammaPrint result, and it will be sent directly to your physician.
The test is performed in a CAP, CLIA accredited & FDA approved Agendia laboratory in Netherlands.
The new MammaPrint technique was developed in the Netherlands by scientists and doctors at the Netherland’s Kanker Institute (Netherlands Cancer Institute) and Antonie van Leeuwenhoek Hospital in Amsterdam.
Researchers compared the genes of patients with early metastasis to the genes of patients with late metastasis or no metastasis at all. It emerged that 70 genes played a role in the formation of metastasis and the spread thereof.
The MammaPrint test is a huge leap forward in the field of diagnosis. Analyzing the 70 genes enables one to predict with greater precision how the cancer is going to progress in the future. This will then enable your physician to tailor your treatment with greater precision. MammaPrint is revolutionary in that it is a highly personalized diagnostic tool. MammaPrint will reveal how your individual tumor is going to develop. MammaPrint accurately predicts the risk of metastasis. This will enable you and your physician to make a more informed choice regarding the best kind of treatment for you in your specific condition. MammaPrint is one of the first products to facilitate tailor made medicine. Your treatment no longer follows a standard protocol, but is based on your individual profile. Your genetic makeup plays a particularly important role in cancer. Your predisposition and shortcomings which occur in your genes determine the development in your cells.
A MammaPrint is performed at Agendia’s laboratory, using microarray chip technology. A microarray is a minute (micro) rectangular plate containing tiny drops of DNA arranged in a matrix pattern (array). Each spot on the microarray contains a piece of DNA of one particular gene, which belongs for example to a human being. In the event of a MammaPrint they would be genes from a piece of breast tissue. Cancer is often caused by overactive genes. It becomes essential to know which specific genes are the causes of the cancer. This can be determined by using a microarray to compare the activity of the genes in healthy cells to the activity of genes in tumor cells.
MammaPrint is a 70-gene test that will assess your cancer’s risk of recurrence or how likely the cancer is to return in the future. You are given definitive results, either a Low Risk or High Risk result, with no intermediate or undetermined results. A Low Risk result means you have a 10% or 1 in 10 chance of your cancer returning. A High Risk result means you have a 29%, or 3 out of 10 chance of it returning. These results are based on a 10-year follow-up of a reference group of patients who had no additional treatment.1 A Low Risk result doesn’t guarantee that your cancer will not recur, and a High Risk result doesn’t guarantee that your cancer will. These results, in addition to all other factors help you and your doctor make the most appropriate breast cancer treatment decisions.
If you are in the Low Risk group, you have a lower chance of the cancer returning, and there is little, if any benefit to getting chemotherapy. Studies have shown the addition of Hormone therapy alone for ER-positive breast cancer can lower the risk of recurrence by up to 50%.
If you are in the High Risk group, the addition of chemotherapy can be considered as part of your treatment plan. High Risk patients can be further divided into subtypes, which can refine your treatment plan. These subtypes provide additional information about what your tumor may respond to best: hormone therapy, chemotherapy, targeted therapy or a combination
Ask your doctor to run the Agendia Breast Cancer Test Suite on your breast cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage (FFPE tissue). No new biopsy or surgical tissue sample is usually required. If your doctor is unfamiliar with Agendia testing, please call Customer Care at 0124-4779800, +91 8506891000 to know more about the test.
Agendia provides a summary page designed for patients to help understand their individual results and have a meaningful discussion with their doctor about treatment options.
BluePrint is a 80-gene test that uncovers your tumor’s functional molecular subtype. Molecular subtyping informs your doctor about how the tumor is functioning underneath the surface. Traditional subtyping (such as IHC or FISH) assess a tumor by looking at cell surface characteristics, while molecular subtyping looks deeper at the functional level, to see which genes are driving the tumor’s behavior. Combined with MammaPrint, BluePrint will determine if your breast cancer is Luminal type (A or B), Basal-type or HER-2 type. These findings are important when deciding which treatment is most appropriate for your specific tumor.
MammaPrint and BluePrint provide you and your doctor deeper insight into tumor pathways, uncovering your hidden tumor biology. By combining risk of recurrence, with molecular subtyping, you get a clearer picture of how your breast cancer is functioning, leading to more informed treatment decision making. MammaPrint is the first FDA cleared breast cancer recurrence assay, and is the only breast cancer recurrence assay backed by peer-reviewed prospective outcome data. BluePrint molecular subtyping is the most widely available molecular subtyping assay that identify your potential level of responsiveness to chemotherapy more accurately than IHC/FISH, with better correlation to long-term clinical treatment outcomes.
Click on the links below to download helpful resource materials:

New Study Could Change Breast Cancer Treatment

WKRN-TV in Nashville covers an important study of BluePrint, a molecular test for individualizing treatment of breast cancer patients, and interviews Nashville-based researcher Pat Whitworth, M.D. Also interviewed is patient Nina Vowell, who chose a treatment approach made possible by tests like BluePrint. She first received pre-operative chemotherapy to shrink her tumor, and then had breast-conserving surgery. This option helped her avoid a mastectomy. Dr. Whitworth notes that only patients who will benefit from chemotherapy should receive it. The NBRST study concluded that BluePrint may be a better guide than IHC-FISH tests in making decisions about how to treat early-stage breast cancer before surgery.

Agendia is a leading molecular diagnostic company focused on oncology that develops and markets FFPE-Based genomic diagnostic products.
Neuropharmagen® is a genetic test developed by AB-BIOTICS SA, a biotechnology company founded in 2004 as a spin-off of the Autonomous University of Barcelona. The company maintains a close relationship with the Faculty of Medicine of the Autonomous University of Barcelona and the University of Girona. iLife Discoveries is the exclusive technology partner to AB Biotics in India.
To perform a genetic test requires a sample of the patient’s DNA. The test is performed through a simple analysis patient’s saliva.
Our group of experts in genetics and molecular biology has found that there is no difference between the results obtained with the saliva test than the blood test. The workshop recommended the use of saliva rather than blood for three reasons: 1.Ability to obtain a sample in situ, without the need for a nurse/phlebotomist, so an non-invasive procedure ensures fast and comfortable process for the patient. 2.The sample can be stored at room temperature (the blood must instead be stored at 4 ° C) until our logistic partner picks it up and couriers it to us; 3.The DNA in the saliva remains stable for 4 weeks (compared to a maximum of 48 h for the blood sample).
Neuropharmagen® is based on the findings of numerous scientific studies conducted over the last decade, which have shown that genetics has a significant impact on each individual’s response to drugs. We are all different from the genetic point of view and these differences mean that each of us responds differently to medications.
Neuropharmagen® is a genetic test used in neurology and psychiatry that, from the patient’s DNA, helps identify the drug most suitable for each individual, thus reducing the time between diagnosis and effective treatment, and helping to identify the right treatment from the outset. The test results allow the physician to: 1. Identify the most suitable drug for the patient; 2. Adjust the dose at the individual level from the start of treatment; 3. Avoid making excessive changes to the treatment; 4. Reduce risk of side effects.
Neuropharmagen® is not a diagnostic test, nor analyzes the causes of the disease. Neuropharmagen® analyzes, through a DNA test, the probability of response to a set of drugs, and then provides the physician a series of information that will help him to choose the most suitable drug and dosage for the patient.
The test is only relevant for drugs that currently have proven pharmacogenetic information, validated through trials and recommended by international guidelines. After reviewing the information published so far, scientists have pooled in the evidences and formulated an algorithm which works on the genotypic data. The list is not exhaustive, more drugs would be a part of this panel, as and when their pharmacogenetic markers are well established.
The test is a high throughput test wherein the sample is evaluated genetically for responses for a range of drugs. It involves genotyping, sequencing and then analyzed for pharmacogenetic implications. It cannot be done for a smaller panel.
For now, the FDA provides only non-binding recommendations. The FDA publishes on its website a list of drugs for which pharmacogenetic testing needs to be done before prescribing.
The laboratory ensures confidentiality of the patient and his/her genetic data obtained and compliance with the Law on the protection of data. The whole process of test requisition, reporting and interpretation is routed through the physician ensuring confidentiality. The whole process is bar coded, and labeled as NFGINXXXXX , and the same reflects back on the report.
If the drug is marked with the word “Standard” means that the analyzed genes linked to this drug doesn’t infer any genetic advantage with respect to response or metabolism. The drug then has to be administered in a way representing the average population. However “Green” represents those drugs, in which the particular person holds a genetic advantage, the drug would have a greater likelihood of a positive response. Therefore, In the absence of other information (patient history, concomitant medications, etc.), the drugs reported in GREEN are preferable to those marked as “Standard”.
The drugs mentioned in “RED” have been found to be associated to more likelihood of adverse drug reactions, with respect to the pharmacogenetic implications true to the genotype of the patient. These drugs, if administered, would likely to initiate adverse and unwarranted drug reactions.
There are many more genetic and environmental factors that significantly affect the response to drugs, which influences a drug response, and this is a very dynamic field, but by giving an informed panel of favorable drugs to the physician, he/she can expect quicker and anticipated response from the patient.
The drugs empanelled in this test include those which have been found to have pharmacogenetic markers validated and established. It is on the discretion of the physician to extrapolate findings for drugs whose markers has still not been characterized.
The result report includes an attachment with information on potential drug-drug interactions with concomitant medications related enzymes of cytochrome P450 metabolism. In the tables are collected the data for the drugs of interest, totally or partially metabolized by major P450 enzymes, and whose metabolism can be influenced by concomitant therapy.
In some cases Neuropharmagen® can confirm the presence of genetic factors likely to be responsible for the lack of response and / or poor tolerability of a group of drugs, which may be due, for example, to an alteration of the metabolic status that affects various psychotropic drugs. Neuropharmagen® will also be useful to propose alternatives and examine any genetic information that can assist physicians in their identification and selection.
At a technical level, the test is reliable to 99.9%. In addition, a clinical study was performed on 21 patients, conducted by Dr.. Jerónimo Saiz and Dr. Miguel Vega Hospital Ramón y Cajal (reference center in the field of psychiatry in Madrid), the results showed that: • L ‘81% of patients were receiving treatment suboptimal or improvable; • Based on the results of the analysis, was proposed modification of therapy in 57% of cases analyzed.
Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth. Using gene expression testing to help design a tailored treatment plan is called personalized medicine. These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer.
Your physician will assess many factors prior to determining your treatment plan. These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.
Ask your doctor to run Ovagene testing on your specific cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage. No new biopsy or surgical tissue sample is typically required. Specialists at iLife Discoveries will assist your doctor in getting this done.
CerviGENETM is a unique tumor profiling test which analyses a panel of genes that will assist you and your physician in determining what would be the best treatment option for your cervical / vaginal tumor.
CerviGENETM is most suitable in all cases of primary or recurrent disease patients where chemotherapy and radiation are treatment options to know whether a drug will or will not bring a desired outcome. Ask your physician whether CerviGENETM would be useful in your condition.
Your physician can request the test to be performed. Please discuss this with your physician.
No, CerviGENETM is not a treatment or cure. It is a tool used to make a more informed choice about therapy selection. It cannot be used to determine how aggressive your type of cancer is. CerviGENETM will however help you decide what would be the most appropriate treatment for you.
You wish to receive the best possible cervical / vaginal cancer treatment. CerviGENETM will enable you to choose a treatment which is specifically tailored to you.
The physician takes a small piece of tissue from the tumors which has been removed, and sends the FFPE Block of this tissue to iLife Discoveries Laboratory.
No, a different kind of test would need to be carried out which focuses on the hereditary forms of cancer, which can be identified by analyzing structural alteration in various genes.
It takes fifteen working days to get the CerviGENETM result, and it will be sent directly to your physician.
The test is performed in a CAP, CLIA accredited Ovagene laboratory in Irvine, CA.
The new CerviGENETM test was developed in the USA by scientists and doctors at the Ovagene Laboratory in Irvine, CA.
A CerviGENETM is performed at Ovagene laboratory, using HTG technology. HTG is a nuclease protection probe based technology which uses a HTG edge system. The technology makes use of a 96 well plate which contains tiny spots of DNA arranged in a matrix pattern.
Each spot in the mictrotitre plate well contains a probe oligonucleotide against one particular gene. Cancer is often caused by altered expression of genes. It becomes essential to know which specific genes are the root causes of the cancer.

Ask your doctor to run the CerviGENETM on your cervical / vaginal cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage (FFPE tissue). No new biopsy or surgical tissue sample is usually required.
If your doctor is unfamiliar with Ovagene testing, please call Customer Care at 0124-4779800, +91 8506891000 to know more about the test.

Ovagene provides a summary page designed for patients to help understand their individual results and have a meaningful discussion with their doctor about treatment options.
Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth. Using gene expression testing to help design a tailored treatment plan is called personalized medicine. These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer.
Your physician will assess many factors prior to determining your treatment plan. These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.
Ask your doctor to run Ovagene testing on your specific cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage. No new biopsy or surgical tissue sample is typically required. Specialists at iLife Discoveries will assist your doctor in getting this done.
EndoGENETM is a unique tumor profiling test which analyses a panel of genes that will assist you and your physician in determining what would be the best treatment option for your Emdometrium / Uterine tumor.
EndoGENETM is most suitable forhigh risk, early stage disease, initially diagnosed late stage diseas or recurrent disease patients where chemotherapy is a treatment option to know whether a drug will or will not bring a desired outcome. Ask your physician whether EndoGENETM would be useful in your condition
Your physician can request the test to be performed. Please discuss this with your physician.
Genomic tests look at your specific tumor’s genes, to help find out what’s driving its growth. Using gene expression testing to help design a tailored treatment plan is called personalized medicine. These are not the same as genetic tests that determine your inherited risk or hereditary predisposition for cancer.
Your physician will assess many factors prior to determining your treatment plan. These factors, along with your tumor’s genomic profile, can help you and your physician make the most informed treatment decisions for your specific type of cancer.

Ask your doctor to run Ovagene testing on your specific cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage. No new biopsy or surgical tissue sample is typically required. Specialists at iLife Discoveries will assist your doctor in getting this done.
OvariGENETM is a unique tumor profiling test which analyses a panel of genes that will assist you and your physician in determining what would be the best treatment option for your ovarian or fallopian tube cancerous tumor.
OvariGENETM is most suitable both platinum resistant and platinum sensitive patients to know whether a drug will or will not bring a desired outcome. Ask your physician whether OvariGENETM would be useful in your condition.
Your physician can request the test to be performed. Please discuss this with your physician.
No, OvariGENETM is not a treatment or cure. It is a tool used to make a more informed choice about therapy selection. It cannot be used to determine how aggressive your type of ovarian cancer is. OvariGENETM will however help you decide what would be the most appropriate treatment for you.
You wish to receive the best possible ovarian / fallopian tube cancer treatment. OvariGENETM will enable you to choose a treatment which is specifically tailored to you.
The physician takes a small piece of tissue from the tumors which has been removed, and sends the FFPE Block of this tissue to iLife Discoveries Laboratory.
No, a different kind of test would need to be carried out which focuses on the hereditary forms of cancer, which can be identified by analyzing structural alteration in various genes.
It takes fifteen working days to get the OvariGENETM result, and it will be sent directly to your physician.
The test is performed in a CAP, CLIA accredited Ovagene laboratory in Irvine, CA.
The new OvariGENETM test was developed in the USA by scientists and doctors at the Ovagene Laboratory in Irvine, CA.
A OvariGENETM is performed at Ovagene laboratory, using HTG technology. HTG is a nuclease protection probe based technology which uses a HTG edge system. The technology makes use of a 96 well plate which contains tiny spots of DNA arranged in a matrix pattern.
Each spot in the mictrotitre plate well contains a probe oligonucleotide against one particular gene. Cancer is often caused by altered expression of genes. It becomes essential to know which specific genes are the root causes of the cancer.

Ask your doctor to run the OvariGENETM on your ovarian cancer. These tests can be run on a sample of your tumor that was removed during biopsy or surgery and was embedded in paraffin for storage (FFPE tissue). No new biopsy or surgical tissue sample is usually required.
If your doctor is unfamiliar with Ovagene testing, please call Customer Care at 0124-4779800, +91 8506891000 to know more about the test.

Ovagene provides a summary page designed for patients to help understand their individual results and have a meaningful discussion with their doctor about treatment options.

WE WOULD LOVE TO HEAR FROM YOU

Contact us